Acadia Claims Success For Nuplazid In A Broader Psychosis Indication

 
• By Jessica Merrill

The company expects to file pimavanserin for the treatment of dementia-related psychosis in 2020, based on the results of a single positive Phase III trial.

Business success concept with target as motivation (3D Rendering) - Illustration
Acadia's pimavanserin trial was stopped early due to efficacy in dementia-related psychosis

More from Neurological

More from Therapy Areas